Literature DB >> 28978958

Vedolizumab in Patients With Common Variable Immune Deficiency and Gut Inflammation.

Brigid S Boland1,2, Marc A Riedl3, Mark A Valasek4, Sheila E Crowe2, William J Sandborn1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28978958      PMCID： PMC6389596          DOI： 10.1038/ajg.2017.246

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN： 0002-9270            Impact factor:   10.864


× No keyword cloud information.
  4 in total

1.  Common variable immunodeficiency: clinical and immunological features of 248 patients.

Authors:  C Cunningham-Rundles; C Bodian
Journal:  Clin Immunol       Date:  1999-07       Impact factor: 3.969

2.  Anti-tumour necrosis factor-alpha therapy for severe enteropathy in patients with common variable immunodeficiency (CVID).

Authors:  I Chua; R Standish; S Lear; M Harbord; E Eren; M Raeiszadeh; S Workman; D Webster
Journal:  Clin Exp Immunol       Date:  2007-09-05       Impact factor: 4.330

3.  Vedolizumab as induction and maintenance therapy for Crohn's disease.

Authors:  William J Sandborn; Brian G Feagan; Paul Rutgeerts; Stephen Hanauer; Jean-Frédéric Colombel; Bruce E Sands; Milan Lukas; Richard N Fedorak; Scott Lee; Brian Bressler; Irving Fox; Maria Rosario; Serap Sankoh; Jing Xu; Kristin Stephens; Catherine Milch; Asit Parikh
Journal:  N Engl J Med       Date:  2013-08-22       Impact factor: 91.245

4.  Gastrointestinal tract pathology in patients with common variable immunodeficiency (CVID): a clinicopathologic study and review.

Authors:  Jason A Daniels; Howard M Lederman; Anirban Maitra; Elizabeth A Montgomery
Journal:  Am J Surg Pathol       Date:  2007-12       Impact factor: 6.394
  4 in total
  6 in total

Review 1.  Autoimmunity in common variable immunodeficiency.

Authors:  Shradha Agarwal; Charlotte Cunningham-Rundles
Journal:  Ann Allergy Asthma Immunol       Date:  2019-07-23       Impact factor: 6.347

Review 2.  Gastrointestinal Manifestations and Complications of Primary Immunodeficiency Disorders.

Authors:  Shradha Agarwal; Charlotte Cunningham-Rundles
Journal:  Immunol Allergy Clin North Am       Date:  2019-02       Impact factor: 3.479

3.  Vedolizumab therapy in common variable immune deficiency associated enteropathy: A case series.

Authors:  Travis Sifers; Robert Hirten; Saurabh Mehandru; Huaibin Mabel Ko; Jean-Frederic Colombel; Charlotte Cunningham-Rundles
Journal:  Clin Immunol       Date:  2020-02-11       Impact factor: 3.969

Review 4.  Primary Humoral Immune Deficiencies: Overlooked Mimickers of Chronic Immune-Mediated Gastrointestinal Diseases in Adults.

Authors:  Ida Judyta Malesza; Michał Malesza; Iwona Krela-Kaźmierczak; Aleksandra Zielińska; Eliana B Souto; Agnieszka Dobrowolska; Piotr Eder
Journal:  Int J Mol Sci       Date:  2020-07-23       Impact factor: 5.923

5.  Vedolizumab Therapy in Refractory Enteropathy Associated With CVID.

Authors:  Dane Johnson; Goo Lee; Frederick Weber
Journal:  ACG Case Rep J       Date:  2021-12-28

6.  Safe and Successful Treatment of Acute Cellular Rejection of an Intestine and Abdominal Wall Transplant With Vedolizumab.

Authors:  Guido Trentadue; Gursah Kats-Ugurlu; Tjasso Blokzijl; Gilles Fh Diercks; Jan Willem Haveman; Klaas Nico Faber; Gerard Dijkstra
Journal:  Transplant Direct       Date:  2020-01-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.